{"id":"oral-corticosteroid-ocs","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia / glucose intolerance"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Osteoporosis / bone loss"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Insomnia and mood changes"},{"rate":null,"effect":"Weight gain and fluid retention"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Cataracts (with chronic use)"}]},"_chembl":{"chemblId":"CHEMBL2108778","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Corticosteroids enter cells and bind to intracellular glucocorticoid receptors, which then translocate to the nucleus and alter the expression of inflammatory genes. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of both innate and adaptive immune responses. The result is broad anti-inflammatory and immunosuppressive effects across multiple organ systems.","oneSentence":"Oral corticosteroids suppress the immune system and reduce inflammation by binding to glucocorticoid receptors in the cytoplasm and modulating gene transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:08.982Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (e.g., rheumatoid arthritis, lupus, vasculitis)"},{"name":"Allergic reactions and asthma exacerbations"},{"name":"Adrenal insufficiency"},{"name":"Certain hematologic malignancies and lymphomas"},{"name":"Organ transplant rejection prophylaxis"}]},"trialDetails":[{"nctId":"NCT04206553","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-10-28","conditions":"Bullous Pemphigoid","enrollment":106},{"nctId":"NCT07221838","phase":"PHASE4","title":"A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab","status":"NOT_YET_RECRUITING","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2026-02-27","conditions":"Generalized Myasthenia Gravis, gMG","enrollment":75},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT06970080","phase":"PHASE4","title":"Therapeutic Relevance of Abnormal Airway Morphology in Asthma","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-06-02","conditions":"Asthma","enrollment":242},{"nctId":"NCT06041386","phase":"PHASE4","title":"REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-03-20","conditions":"Asthma","enrollment":336},{"nctId":"NCT05061771","phase":"PHASE3","title":"Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)","status":"WITHDRAWN","sponsor":"AKARI Therapeutics","startDate":"2022-05-06","conditions":"Bullous Pemphigoid","enrollment":""},{"nctId":"NCT06580600","phase":"NA","title":"PREcision Medicine Directed Corticosteroids In Children With preSchool Wheeze","status":"RECRUITING","sponsor":"Queen's University, Belfast","startDate":"2024-11-04","conditions":"Wheezing","enrollment":120},{"nctId":"NCT03620747","phase":"PHASE3","title":"Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-08-30","conditions":"Asthma","enrollment":393},{"nctId":"NCT05750797","phase":"","title":"The Nationwide Real-world Status of Oral Corticosteroid Use in Patients With Asthma","status":"UNKNOWN","sponsor":"Joon Young Choi","startDate":"2023-03-01","conditions":"Asthma, Corticosteroid","enrollment":800000},{"nctId":"NCT03782532","phase":"PHASE3","title":"Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-01-25","conditions":"Asthma","enrollment":486},{"nctId":"NCT05129033","phase":"NA","title":"A Prospective Study on Optimizing Treatment for ABPA","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-11-15","conditions":"Allergic Bronchopulmonary Aspergillosis","enrollment":100},{"nctId":"NCT02501629","phase":"PHASE3","title":"An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2015-09-29","conditions":"Asthma, Elevated Blood Eosinophils, Oral Corticosteroid Dependence","enrollment":177},{"nctId":"NCT03934801","phase":"","title":"Expert Statements Concerning the Tapering of Oral Corticosteroids (OCS) for the Treatment of Asthma","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2019-04-01","conditions":"Asthma","enrollment":140},{"nctId":"NCT02528214","phase":"PHASE3","title":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-10-15","conditions":"Asthma","enrollment":210},{"nctId":"NCT03899740","phase":"","title":"Expert Statements Concerning the Tapering of Oral Corticosteroids (OCS) for the Treatment of Asthma","status":"UNKNOWN","sponsor":"Association Jean Baptiste Desbrest","startDate":"2019-04-01","conditions":"Asthma","enrollment":30},{"nctId":"NCT02753764","phase":"PHASE2","title":"Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma","status":"COMPLETED","sponsor":"National Jewish Health","startDate":"2017-01","conditions":"Corticosteroid Resistant (CR) Asthmatics","enrollment":2},{"nctId":"NCT02281357","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-02-19","conditions":"Asthma","enrollment":140},{"nctId":"NCT02075255","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-04-28","conditions":"Asthma","enrollment":220},{"nctId":"NCT02336425","phase":"PHASE2","title":"Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09","conditions":"Asthma","enrollment":10},{"nctId":"NCT01987492","phase":"PHASE2","title":"A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-02-28","conditions":"Asthma","enrollment":230},{"nctId":"NCT01395875","phase":"","title":"Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2849},{"nctId":"NCT01691508","phase":"PHASE3","title":"Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10","conditions":"Asthma","enrollment":135},{"nctId":"NCT01948401","phase":"PHASE2","title":"A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07","conditions":"Asthma","enrollment":54},{"nctId":"NCT02013076","phase":"","title":"Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth","status":"COMPLETED","sponsor":"St. Justine's Hospital","startDate":"2011-01","conditions":"Asthma","enrollment":1011}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["prednisone"],"phase":"marketed","status":"active","brandName":"Oral Corticosteroid (OCS)","genericName":"Oral Corticosteroid (OCS)","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oral corticosteroids, such as prednisone and prednisolone, are used to treat conditions including asthma and bullous pemphigoid. They are also used in combination with dupilumab in clinical trials for severe steroid-dependent asthma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}